Literature DB >> 35693393

Development and internal validation of the Comprehensive ALPPS Preoperative Risk Assessment (CAPRA) score.

Junwei Zhang1, Huayu Yang1, Xin Lu1, Yiyao Xu1.   

Abstract

Entities:  

Year:  2022        PMID： 35693393      PMCID： PMC9186201          DOI： 10.21037/hbsn-22-158

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   8.265


× No keyword cloud information.
  10 in total

1.  Early survival and safety of ALPPS: first report of the International ALPPS Registry.

Authors:  Erik Schadde; Victoria Ardiles; Ricardo Robles-Campos; Massimo Malago; Marcel Machado; Roberto Hernandez-Alejandro; Olivier Soubrane; Andreas A Schnitzbauer; Dimitri Raptis; Christoph Tschuor; Henrik Petrowsky; Eduardo De Santibanes; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2014-11       Impact factor: 12.969

2.  The ALPPS Risk Score: Avoiding Futile Use of ALPPS.

Authors:  Michael Linecker; Gregor A Stavrou; Karl J Oldhafer; Robert M Jenner; Burkhardt Seifert; Georg Lurje; Jan Bednarsch; Ulf Neumann; Ivan Capobianco; Silvio Nadalin; Ricardo Robles-Campos; Eduardo de Santibañes; Massimo Malagó; Mickael Lesurtel; Pierre-Alain Clavien; Henrik Petrowsky
Journal:  Ann Surg       Date:  2016-11       Impact factor: 12.969

3.  Liver resection in the elderly: significance of comorbidities and blood loss.

Authors:  Tobias S Schiergens; Carsta Stielow; Stefanie Schreiber; Cyrill Hornuss; Karl-Walter Jauch; Markus Rentsch; Wolfgang E Thasler
Journal:  J Gastrointest Surg       Date:  2014-04-09       Impact factor: 3.452

4.  Impact of split completeness on future liver remnant hypertrophy in associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in hepatocellular carcinoma: Complete-ALPPS versus partial-ALPPS.

Authors:  Albert C Y Chan; Kenneth Chok; Jeff W C Dai; Chung Mau Lo
Journal:  Surgery       Date:  2016-09-03       Impact factor: 3.982

5.  Development and internal validation of the Comprehensive ALPPS Preoperative Risk Assessment (CAPRA) score: is the patient suitable for Associating Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS)?

Authors:  Ivan Capobianco; Karl J Oldhafer; Mohammed-Hossein Fard-Aghaie; Ricardo Robles-Campos; Roberto Brusadin; Henrik Petrowsky; Michael Linecker; Arianeb Mehrabi; Katrin Hoffmann; Jun Li; Asmus Heumann; Roberto Hernandez-Alejandro; Mauro Enrique Tun-Abraham; Elio Jovine; Matteo Serenari; Bergthor Bjornsson; Per Sandström; Ruslan Alikhanov; Mikhail Efanov; Paolo Muiesan; Andrea Schlegel; Thomas M van Gulik; Pim B Olthof; Gregor Alexander Stavrou; Lina Maria Serna-Higuita; Alfred Königsrainer; Silvio Nadalin
Journal:  Hepatobiliary Surg Nutr       Date:  2022-02       Impact factor: 7.293

6.  Acute kidney injury after associating liver partition and portal vein ligation for staged hepatectomy for hepatocellular carcinoma: two case reports and a literature review.

Authors:  Hanchun Huang; Xin Lu; Huayu Yang; Yiyao Xu; Xinting Sang; Haitao Zhao
Journal:  Ann Transl Med       Date:  2019-12

7.  How should liver hypertrophy be stimulated? A comparison of upfront associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) and portal vein embolization (PVE) with rescue possibility.

Authors:  Ernesto Sparrelid; Kristina Hasselgren; Bård Ingvald Røsok; Peter Nørgaard Larsen; Nicolai Aagaard Schultz; Ulrik Carling; Eva Fallentin; Stefan Gilg; Per Sandström; Gert Lindell; Bergthor Björnsson
Journal:  Hepatobiliary Surg Nutr       Date:  2021-01       Impact factor: 7.293

Review 8.  Uncommon indications for associating liver partition and portal vein ligation for staged hepatectomy: a systematic review.

Authors:  Quirino Lai; Gianluca Mennini; Zoe Larghi Laureiro; Massimo Rossi
Journal:  Hepatobiliary Surg Nutr       Date:  2021-04       Impact factor: 8.265

Review 9.  A better route to ALPPS: minimally invasive vs open ALPPS.

Authors:  Kawka Michal; Mak Sau; Gall M H Tamara; Jiao R Long
Journal:  Surg Endosc       Date:  2020-04-09       Impact factor: 4.584
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.